Evidence map›Paper›PMID 42135753›Full record

ArticleCancer cell international2026

HER2-targeted doxorubicin-loaded cell-derived extracellular vesicles induce apoptosis of breast cancer cells via ROS/TXNIP pathway activation.

Chan Mi Lee, Do Sang Lee, Ji Won Choi, Joo Won Moon, Jiwon Park, Soo Youn Bae

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chan Mi LeeDepartment of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Do Sang LeeDepartment of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Ji Won ChoiSeoul St. Mary's Hospital, College of Medicine, Catholic University of Korea Central Institute of Surgery, The Catholic University of Korea, Seoul, South Korea.
Joo Won MoonSeoul St. Mary's Hospital, College of Medicine, Catholic University of Korea Central Institute of Surgery, The Catholic University of Korea, Seoul, South Korea.
Jiwon ParkSeoul St. Mary's Hospital, College of Medicine, Catholic University of Korea Central Institute of Surgery, The Catholic University of Korea, Seoul, South Korea.
Soo Youn BaeDepartment of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. baessu@gmail.com.ORCID http://orcid.org/0000-0003-0551-7618

Funding

National Research Foundation of Korea RS-2025-00520440
6 · The paper itself

Abstract

backgroundSystemic toxicity and limited tumor selectivity remain major obstacles in HER2-positive breast cancer therapy with conventional chemotherapeutics. Extracellular vesicles (EVs) provide a promising delivery platform due to their intrinsic biocompatibility and intercellular communication. Here, we engineered EVs displaying the HER2-binding peptide P51 to create a peptide-mediated targeted delivery system for doxorubicin (Dox), aiming to enhance tumor specificity and apoptotic efficacy.

methodsEVs expressing the P51 peptide were generated by transient transfection of HEK-293 cells, followed by Dox loading to produce P51-EV

resultsP51-EV

conclusionsThis study demonstrates that peptide-functionalized EVs represent a promising tumor-targeted chemotherapeutic platform for HER2-positive breast cancer. By integrating ligand-mediated cellular recognition with EV-based doxorubicin delivery, P51-EV

Indexed as

ApoptosisExtracellular vesicles (EVs)HER2-positive breast cancerPeptide-engineered EVsROS/TXNIP pathway

Identifiers

PMID42135753
PMCPMC13343990

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.